NovoMedix, LLC
USPTO PatentsView assignee record - 7 granted patents across 5 technology areas, recorded in grant years 2015–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Novomedix ranks #36,744 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 5 technology areas.
- #36,744
- of 49,997 US assignees by volume
- Top 49%
- by Innovation Score (35.6/100)
- 23.1
- avg claims per patent
- -60%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R36744 · US Corporation #36,744 · 7 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 7 grants
- MID-PACK #36,744/49,997
- PHOTO-FINISH Nottingham Spirk…
- CPC-NARROW A61P · 5 areas
- INNOV-THIN 35.6/100
- CLAIMS-DENSE 23.1 claims/avg
- TYPE-USCORP US Corporation
- VEL-DROP -60% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Nottingham Spirk Design Associates (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Novomedix’s 35.6 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Novomedix
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Flow Neuroscience · near
Flow Neuroscience · near
36 score
- Handstands Promo · near
Handstands Promo · near
36 score
- NovoMedix · this assignee
NovoMedix · this assignee
36 score
- Sanoculis · near
Sanoculis · near
36 score
- Shenzhen Yunyinggu… · near
Shenzhen Yunyinggu… · near
36 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Novomedix's Innovation Score is 35.6/100 (top 49% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Novomedix?
Each dot is one of Novomedix’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Novomedix’s own 23.1 claims/patent is ABOVE the 16.9 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Novomedix's grants concentrate
NovoMedix, LLC is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (2 grants) versus a trough of 1 in 2018. By volume, Novomedix sits between Nottingham Spirk Design Associates and Nuix Pty Ltd.
Novomedix's three-year grant acceleration
NovoMedix, LLC shows 1 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at NovoMedix's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Nottingham Spirk…
Nottingham Spirk Design Associates
7 patents
- Nous Defions
Nous Defions, LLC
7 patents
- Novaplast
Novaplast Corporation
7 patents
- Novar ED&S
Novar ED&S Limited
7 patents
- Novvi
Novvi LLC
7 patents
- Nowdiagnostics
NowDiagnostics, Inc.
7 patents
- Nucript
Nucript LLC
7 patents
- Nuix Pty
Nuix Pty Ltd
7 patents
- Novomedix ◀
NovoMedix, LLC
7 patents
What this shows NovoMedix holds 7 patents at rank #36,739, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near NovoMedix
By rank, the assignees closest to #36,739 in granted patent volume.
- Nottingham Spirk Design Associates #36,735 · 7 patents
- Nous Defions, LLC #36,736 · 7 patents
- Novaplast Corporation #36,737 · 7 patents
- Novar ED&S Limited #36,738 · 7 patents
- Novvi LLC #36,740 · 7 patents
- NowDiagnostics, Inc. #36,741 · 7 patents
- Nucript LLC #36,742 · 7 patents
- Nuix Pty Ltd #36,743 · 7 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in NovoMedix's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Assignees with similar portfolio profiles
Two PlainPatent-derived peer sets for NovoMedix, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), NovoMedix ranks #2,588 of 6,058 assignees by patent count in that subclass.
Similar innovation score
Nearest assignees by Innovation Score (36 here).
Novomedix's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
36 Top 49% higher than 51% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 2 | 28.6% |
| 2017 | 2 | 28.6% |
| 2018 | 1 | 14.3% |
| 2021 | 1 | 14.3% |
| 2023 | 1 | 14.3% |
Which technologies does NovoMedix, LLC patent most?
Top 5 of 5 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
NovoMedix, LLC's patent record in context - here's where to go next.
- NovoMedix, LLC's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #36,744 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare NovoMedix, LLC against Nottingham Spirk Design Associates, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 35.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.